FIG 5.
The effect of amikacin-fosfomycin combination therapy on the density of resistant bacterial populations of a K. pneumoniae clinical isolate (K.p. 301) in an HFIM simulating pharmacokinetic decay of peak concentrations of 300 mg/liter amikacin–1,200 mg/liter fosfomycin in comparison with growth with monotherapy with each antibiotic.